PLoS ONE (Jan 2011)

Platelets in patients with premature coronary artery disease exhibit upregulation of miRNA340* and miRNA624*.

  • Brigitte M Sondermeijer,
  • Annemieke Bakker,
  • Amalia Halliani,
  • Maurice W J de Ronde,
  • Arnoud A Marquart,
  • Anke J Tijsen,
  • Ties A Mulders,
  • Maayke G M Kok,
  • Suzanne Battjes,
  • Steffi Maiwald,
  • Suthesh Sivapalaratnam,
  • Mieke D Trip,
  • Perry D Moerland,
  • Joost C M Meijers,
  • Esther E Creemers,
  • Sara-Joan Pinto-Sietsma

DOI
https://doi.org/10.1371/journal.pone.0025946
Journal volume & issue
Vol. 6, no. 10
p. e25946

Abstract

Read online

BackgroundCoronary artery disease (CAD) is the leading cause of human morbidity and mortality worldwide, underscoring the need to improve diagnostic strategies. Platelets play a major role, not only in the process of acute thrombosis during plaque rupture, but also in the formation of atherosclerosis itself. MicroRNAs are endogenous small non-coding RNAs that control gene expression and are expressed in a tissue and disease-specific manner. Therefore they have been proposed to be useful biomarkers. It remains unknown whether differences in miRNA expression levels in platelets can be found between patients with premature CAD and healthy controls.Methodology/principal findingsIn this case-control study we measured relative expression levels of platelet miRNAs using microarrays from 12 patients with premature CAD and 12 age- and sex-matched healthy controls. Six platelet microRNAs were significantly upregulated (miR340*, miR451, miR454*, miR545:9.1. miR615-5p and miR624*) and one miRNA (miR1280) was significantly downregulated in patients with CAD as compared to healthy controls. To validate these results, we measured the expression levels of these candidate miRNAs by qRT-PCR in platelets of individuals from two independent cohorts; validation cohort I consisted of 40 patients with premature CAD and 40 healthy controls and validation cohort II consisted of 27 patients with artery disease and 40 healthy relatives. MiR340* and miR624* were confirmed to be upregulated in patients with CAD as compared to healthy controls in both validation cohorts.Conclusion/significanceTwo miRNAs in platelets are significantly upregulated in patients with CAD as compared to healthy controls. Whether the two identified miRNAs can be used as biomarkers and whether they are cause or consequence of the disease remains to be elucidated in a larger prospective study.